

Biotherapeutic Process Development Solutions




Overview

The process development at Biopharma Division of Veeda is equipped for expression and purification of heterologous proteins in microbial and mammalian cells (CHO; HEK) for therapeutic and non-therapeutic proteins with process development and scale-up at 2 L and 5 L bioreactors. The cell line development is supported by analytical and assay biology departments for evaluation of critical qualities, enhancing the early development of cell substrates for biosimilars and other biologics.

Process development area has separate labs for handling different activities with clean room for cell line development and upstream processes in a GLP and GMP compliance ways.

**Cell Line
Development**

**Process
Development**



Cell line Development




Microbial and Mammalian Cell Lines

Microbial

- Cloning and expression of recombinant heterologous proteins
- Protein expression optimization (media, feed, inducer conc., induction time)
- Protein purification and characterization by SDS-PAGE and Western blotting
- Host cell characterization (Purity, strain identification and plasmid copy numbers)

- Cloning, expression and purification of recombinant heterologous proteins
- Cell line development for biosimilars and biologics
- Protein purification process development
- RCB preparation and characterization (purity, sterility and stability)

Mammalian



Stable Pool Creation

- Vector Design
- Host Selection
- Stable Transfection


Single Cell Cloning

- Single Cell Isolation
- RCB

Growth & Expansion

- Static / Fed-batch Expansion
- Cell Banking

Banking of Top Clones



Process Development

Mammalian

Process development & Optimization (10/30/500 mL)

- Bioreactor suitability
- Media/feed screening
- Feeding strategy
- Process parameters
- (pH, temperature, dO₂, dCO₂, pressure, agitation)



Process scale-up at 2L /5L scale

- Feeding strategies
- Aeration strategies
- PH
- Material generation




Harvest clarification

- Centrifugation
- Filtration



Centrifugation Filtration

- Affinity chromatography
- Ion-exchange chromatography
- Size exclusion chromatography
- Hydrophobic interaction chromatography
- Filtration
- Concentration



Cell Line / Clone Selection

- Protein sequence verification
- Sequence variants characterization
- Post-translational modification (PTM) analysis
- Glycosylation analysis
- de novo sequencing

Upstream

- Harvest titers
- Identity
- Purity
- Glycosylation analysis
- Post-translational modification analysis


Downstream

- Size and charge variants
- Refolding efficiency
- Identity
- Purity
- Heterogeneity
- Impurity characterization
- N-/O-glycans
- Residuals
- Potency


In-house Development Data

Monoclonal Antibodies


Growth Profiles of in-house mAb Clones in 2L Bioreactor Studies




Productivity of in-house mAb Clones in 2L Bioreactor Studies



Glycosylation profile of innovator and in-house clone



Ligand binding evaluation



State-of-the-Art Process Technologies



+91 7967773000



info@veedacr.com



www.veedacr.com

Partners in creating a healthier tomorrow